Posted by Michael Wonder on 10 Nov 2018
Karyopharm’s selinexor receives fast track designation from FDA for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma
7 November 2018 - Karyopharm Therapeutics today announced that the U.S. FDA has granted fast track designation to selinexor, the Company’s first-in-class, oral SINE compound for the treatment of patients with diffuse large B-cell lymphoma who have received at least two prior therapies and are not eligible for high dose chemotherapy with stem cell rescue or CAR-T therapy.
Karyopharm previously received fast track designation for selinexor as a potential new treatment for patients with penta-refractory multiple myeloma who have received at least three prior lines of therapy.
In October 2018, the U.S. FDA accepted Karyopharm’s new drug application for selinexor seeking accelerated approval as a new treatment for patients with penta-refractory multiple myeloma.
